vs
Side-by-side financial comparison of GLOBAL INDUSTRIAL Co (GIC) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
GLOBAL INDUSTRIAL Co is the larger business by last-quarter revenue ($345.6M vs $196.9M, roughly 1.8× Pacira BioSciences, Inc.). On growth, GLOBAL INDUSTRIAL Co posted the faster year-over-year revenue change (14.3% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $19.2M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs 3.4%).
Global Industrial Company is a Port Washington, New York–based company providing industrial and MRO products through a system of branded e-Commerce websites and relationship marketers in North America. The primary brand is Global Industrial.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
GIC vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $345.6M | $196.9M |
| Net Profit | $14.6M | — |
| Gross Margin | 34.5% | 79.5% |
| Operating Margin | 5.7% | 1.2% |
| Net Margin | 4.2% | — |
| Revenue YoY | 14.3% | 5.1% |
| Net Profit YoY | 36.4% | — |
| EPS (diluted) | $0.37 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $345.6M | $196.9M | ||
| Q3 25 | $353.6M | $179.5M | ||
| Q2 25 | $358.9M | $181.1M | ||
| Q1 25 | $321.0M | $168.9M | ||
| Q4 24 | $302.3M | $187.3M | ||
| Q3 24 | $342.4M | $168.6M | ||
| Q2 24 | $347.8M | $178.0M | ||
| Q1 24 | $323.4M | $167.1M |
| Q4 25 | $14.6M | — | ||
| Q3 25 | $18.8M | $5.4M | ||
| Q2 25 | $25.1M | $-4.8M | ||
| Q1 25 | $13.6M | $4.8M | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $16.8M | $-143.5M | ||
| Q2 24 | $20.3M | $18.9M | ||
| Q1 24 | $13.2M | $9.0M |
| Q4 25 | 34.5% | 79.5% | ||
| Q3 25 | 35.6% | 80.9% | ||
| Q2 25 | 37.1% | 77.4% | ||
| Q1 25 | 34.9% | 79.7% | ||
| Q4 24 | 33.8% | 78.7% | ||
| Q3 24 | 34.0% | 76.9% | ||
| Q2 24 | 35.2% | 75.1% | ||
| Q1 24 | 34.3% | 71.6% |
| Q4 25 | 5.7% | 1.2% | ||
| Q3 25 | 7.4% | 3.5% | ||
| Q2 25 | 9.3% | 4.7% | ||
| Q1 25 | 5.7% | 1.2% | ||
| Q4 24 | 4.8% | 13.2% | ||
| Q3 24 | 6.5% | -82.8% | ||
| Q2 24 | 7.6% | 15.9% | ||
| Q1 24 | 5.4% | 7.9% |
| Q4 25 | 4.2% | — | ||
| Q3 25 | 5.3% | 3.0% | ||
| Q2 25 | 7.0% | -2.7% | ||
| Q1 25 | 4.2% | 2.8% | ||
| Q4 24 | 3.5% | — | ||
| Q3 24 | 4.9% | -85.1% | ||
| Q2 24 | 5.8% | 10.6% | ||
| Q1 24 | 4.1% | 5.4% |
| Q4 25 | $0.37 | $0.05 | ||
| Q3 25 | $0.48 | $0.12 | ||
| Q2 25 | $0.65 | $-0.11 | ||
| Q1 25 | $0.35 | $0.10 | ||
| Q4 24 | $0.28 | $0.38 | ||
| Q3 24 | $0.44 | $-3.11 | ||
| Q2 24 | $0.52 | $0.39 | ||
| Q1 24 | $0.34 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $67.5M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $313.2M | $693.1M |
| Total Assets | $580.8M | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $67.5M | $238.4M | ||
| Q3 25 | $67.2M | $246.3M | ||
| Q2 25 | $55.1M | $445.9M | ||
| Q1 25 | $39.0M | $493.6M | ||
| Q4 24 | $44.6M | $484.6M | ||
| Q3 24 | $38.9M | $453.8M | ||
| Q2 24 | $38.8M | $404.2M | ||
| Q1 24 | $29.9M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $313.2M | $693.1M | ||
| Q3 25 | $316.0M | $727.2M | ||
| Q2 25 | $305.2M | $757.8M | ||
| Q1 25 | $287.9M | $798.5M | ||
| Q4 24 | $281.1M | $778.3M | ||
| Q3 24 | $279.2M | $749.6M | ||
| Q2 24 | $270.4M | $879.3M | ||
| Q1 24 | $260.2M | $892.2M |
| Q4 25 | $580.8M | $1.3B | ||
| Q3 25 | $602.5M | $1.3B | ||
| Q2 25 | $586.5M | $1.5B | ||
| Q1 25 | $536.7M | $1.6B | ||
| Q4 24 | $520.7M | $1.6B | ||
| Q3 24 | $531.6M | $1.5B | ||
| Q2 24 | $542.5M | $1.6B | ||
| Q1 24 | $517.4M | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.0M | $43.7M |
| Free Cash FlowOCF − Capex | $19.2M | $43.5M |
| FCF MarginFCF / Revenue | 5.6% | 22.1% |
| Capex IntensityCapex / Revenue | 0.2% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.37× | — |
| TTM Free Cash FlowTrailing 4 quarters | $74.7M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $20.0M | $43.7M | ||
| Q3 25 | $22.7M | $60.8M | ||
| Q2 25 | $31.7M | $12.0M | ||
| Q1 25 | $3.4M | $35.5M | ||
| Q4 24 | $15.9M | $33.1M | ||
| Q3 24 | $9.6M | $53.9M | ||
| Q2 24 | $18.8M | $53.2M | ||
| Q1 24 | $6.4M | $49.1M |
| Q4 25 | $19.2M | $43.5M | ||
| Q3 25 | $22.0M | $57.0M | ||
| Q2 25 | $30.3M | $9.3M | ||
| Q1 25 | $3.2M | $26.9M | ||
| Q4 24 | $15.2M | $31.0M | ||
| Q3 24 | $8.7M | $49.8M | ||
| Q2 24 | $17.9M | $51.6M | ||
| Q1 24 | $5.1M | $46.3M |
| Q4 25 | 5.6% | 22.1% | ||
| Q3 25 | 6.2% | 31.7% | ||
| Q2 25 | 8.4% | 5.1% | ||
| Q1 25 | 1.0% | 15.9% | ||
| Q4 24 | 5.0% | 16.6% | ||
| Q3 24 | 2.5% | 29.6% | ||
| Q2 24 | 5.1% | 29.0% | ||
| Q1 24 | 1.6% | 27.7% |
| Q4 25 | 0.2% | 0.1% | ||
| Q3 25 | 0.2% | 2.2% | ||
| Q2 25 | 0.4% | 1.5% | ||
| Q1 25 | 0.1% | 5.1% | ||
| Q4 24 | 0.2% | 1.1% | ||
| Q3 24 | 0.3% | 2.4% | ||
| Q2 24 | 0.3% | 0.9% | ||
| Q1 24 | 0.4% | 1.7% |
| Q4 25 | 1.37× | — | ||
| Q3 25 | 1.21× | 11.20× | ||
| Q2 25 | 1.26× | — | ||
| Q1 25 | 0.25× | 7.37× | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 0.57× | — | ||
| Q2 24 | 0.93× | 2.82× | ||
| Q1 24 | 0.48× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GIC
Segment breakdown not available.
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
